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Background
S/GSK1349572(572) showed potent activity in Phase 2
studies in INI-naive HIV-infected subjects and limited
cross-resistance to raltegravir (RAL) and elvitegravir in
vitro. VIKING is an ongoing 24-week Phase 2b pilot
study assessing 572 in subjects with RAL-resistant HIV.
A good antiviral response during the functional mono-
therapy phase (through Day 11) of this pilot study was
observed with a strong correlation between baseline sus-
ceptibility to 572 and response.
Methods
27 RAL-experienced, adult subjects, with screening
plasma HIV-1 RNA ≥1000c/mL and genotypic resis-
tance to RAL and ≥ 2 other ART classes, received 572
50mg QD in Cohort I while continuing their failing
regimen (without RAL). At Day 11 the background regi-
men was optimised, where feasible, and 572 continued.
The antiviral activity (primary end-point at Day 11), tol-
erability, safety and virology data through Week 24 of
Cohort I are presented. A higher dose is being assessed.
Results
At Baseline, subjects harboured viruses displaying high
level resistance to RAL (median fold change in suscept-
ibility [FC] 161, range: 0.57- >166) and low median FC
to 572 (1.46, range: 0.55-35). Median (IQR) Baseline
C D 4 +a n dp l a s m aH I V - 1R N Aw e r e1 1 0c e l l s / m m
3 (40,
230) and 4.47 log10c/mL (3.9, 4.9), respectively. Median
number (range) of prior ART drugs was 18 (10, 23).
Twenty one (78%) subjects achieved plasma HIV-1
RNA<400 c/mL (n=11) or ≥ 0.7 log10 c/mL decline
(n=10) at Day 11 (primary end-point). Post Day 11, the
optimised background regimen (OBR) phenotypic sus-
ceptibility score (PSS) was 0, 1 and ≥ 2 for 12 (44%), 7
(26%) and 8 (30%) subjects, respectively. 17 subjects
continued therapy through Week 24 when 14/27 (52%)
and 11/27 (41%) subjects achieved < 400 c/mL and < 50
c/mL, respectively by TLOVR. Response correlated with
OBR PSS: 2/12 (17%) subjects with PSS =0, 4/7 (57%)
with PSS=1 and 8/8 (100%) with PSS ≥2 achieved <400
c/mL at Week 24. Drug related AEs (any grade) were
observed in 6 (22%) subjects. Two subjects with
advanced AIDS died after withdrawal from study for
SAEs (brain mass, non-Hodgkin’s lymphoma with febrile
bone marrow aplasia) unrelated to 572.
Conclusions
Despite high level baseline resistance to RAL and the
limited activity of the OBR co-administered with 572,
the majority of subjects achieved < 400 c/mL at Week
24 with improved response rates in those receiving at
least one active background ART. S/GSK1349572 was
generally well tolerated in this advanced population.
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